All Stories

  1. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  2. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  3. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  4. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  5. Message From the Editors to Our Reviewers
  6. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  7. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  8. Message From the Editors to Our Reviewers
  9. List of Reviewers
  10. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  11. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  12. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  13. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  14. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  15. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  16. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  17. Message From the Editors to Our Reviewers
  18. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  19. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  20. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  21. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  22. Acknowledgement to Reviewers
  23. Message From the Editors to Our Reviewers
  24. List of Reviewers
  25. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  26. Acknowledgement
  27. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  28. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  29. Message From the Editors to Our Reviewers
  30. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  31. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  32. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  33. Vascular cognitive impairment and dementia: An early career researcher perspective
  34. Message From the Editors to Our Reviewers
  35. List of Reviewers
  36. Acknowledgement
  37. Message From the Editors to Our Reviewers
  38. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  39. Abstract Anne H Berman – incoming ISBM president
  40. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  41. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  42. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  43. Acknowledgements to Reviewers
  44. Swallowing in behavioral variant frontotemporal dementia
  45. Message From the Editors to Our Reviewers
  46. List of Reviewers
  47. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  48. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  49. Dementia in Latin America: Paving the way toward a regional action plan
  50. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  51. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  52. Neuropsychiatric feature profiles of patients with Lewy body dementia
  53. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  54. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  55. Acknowledgments
  56. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  57. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  58. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  59. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  60. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  61. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  62. Acknowledgements to Reviewers
  63. Acknowledgments
  64. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  65. Author Index
  66. Keyword Index
  67. Movement Disorders: Volume 33, Number S2, October 2018
  68. Abstracts
  69. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  70. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  71. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  72. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  73. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  74. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  75. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  76. Acknowledgement to reviewers
  77. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  78. Acknowledgements to Reviewers
  79. ePresentation
  80. ePoster Session
  81. Author Index
  82. Issue Information
  83. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  84. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  85. Reviewers for International Journal of Stroke 2016
  86. Neurological impressions on the organization of language networks in the human brain
  87. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  88. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  89. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  90. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  91. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  92. Swallowing in primary progressive aphasia
  93. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  94. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  95. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  96. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  97. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  98. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  99. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  100. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  101. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  102. Acknowledgements
  103. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  104. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  105. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  106. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  107. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  108. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  109. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  110. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  111. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  112. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  113. 2013 Reviewer Acknowledgement
  114. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  115. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  116. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  117. Cognitive Impairment in Fibromyalgia
  118. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  119. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  120. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  121. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  122. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  123. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  124. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  125. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  126. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  127. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  128. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  129. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  130. Semantic aphasia as a sole manifestation of acute stroke
  131. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  132. Short-term prognosis for speech and language in first stroke patients
  133. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  134. Author Index
  135. Abstracts
  136. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  137. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom